PLX Valuation

Protalix Biotherapeutics Inc

Add to Watchlist

Advanced Chart

1.580

+0.06(3.947%)1D

Overview
Forecast
Valuation
Earnings

PLX Relative Valuation

PLX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PLX is overvalued; if below, it's undervalued.

Historical Valuation

Protalix Biotherapeutics Inc (PLX) is now in the Fair zone, suggesting that its current forward PS ratio of 1.69 is considered Fairly compared with the five-year average of 0.34. The fair price of Protalix Biotherapeutics Inc (PLX) is between 0.93 to 2.66 according to relative valuation methord.

Relative Value

Fair Zone

0.93-2.66

Current Price：1.58

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

2.63

P/B

Median3y

13.09

Median5y

19.50

-1.35

FCF Yield

Median3y

-11.79

Median5y

-15.97

Competitors Valuation Multiple

The average P/S ratio for PLX's competitors is 1.27, providing a benchmark for relative valuation. Protalix Biotherapeutics Inc Corp (PLX) exhibits a P/S ratio of 1.69, which is 32.91% above the industry average. Given its robust revenue growth of 169.82%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

PLX.A

Protalix Biotherapeutics Inc

1.69

Average P/S: 1.27

169.82%